334 results on '"McAleese, J."'
Search Results
52. Improving the reporting of in-patient deaths in an oncology department
53. EP-1340: Comparing dosimetry and toxicity of 5-field IMRT versus VMAT for prostate & pelvic nodal irradiation
54. 129: Survival for patients following radical radiotherapy in the Northern Ireland cancer network in comparison to a large European cohort
55. 134: Marked variability in the access to curative radiotherapy for NSCLC in the UK
56. 135: Re-plan rates for radical radiotherapy in lung cancer
57. Consultant-Led Radiation Therapy Plan Peer Review Meeting and Improved Access to and Outcomes From Curative Intent Lung Cancer Radiation Therapy
58. Salvage radiotherapy for relapsed non-small cell lung cancer (NSCLC). Is it worth it?
59. Audit of metastatic spinal cord compression
60. Ninety-day mortality for radical lung radiotherapy
61. EP-1238: Thoracic re-irradiation following curative intent radiotherapy for non-small cell lung cancer
62. 140 Outcomes of salvage radiotherapy in the treatment of NSCLC with loco-regional relapse
63. 151 The incidence of thoracic re-irradiation at 3 UK cancer centres following curative intent radiotherapy for non-small cell lung cancer
64. 160: Review of the national lung cancer audit of SCLC chemotherapy rates in Northern Ireland
65. 151: A UK survey of the practice of re-irradiation of locally relapsed lung cancers after previous thoracic radiotherapy
66. 162: Review of SCLC timelines to assessment and treatment in Northern Ireland
67. The Impact of Colleague Peer-review on the Radiotherapy Treatment Planning Process in the Radical Treatment of Lung Cancer
68. 160 The impact of peer review on the radiotherapy treatment planning process in the treatment of lung cancer
69. 210 The first UK audit of curative-intent radiotherapy for non-small cell lung cancer; the need to assess quality and improve outcomes
70. Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer
71. Impact of 4-Dimensional CT (4D-CT) on Toxicity, Outcomes, and Dose Escalation for Radical Lung Cancer Radiation Therapy
72. 153 Comparison of PTV geometrics and toxicity between 4DCT and 3DCT for radical treatment of lung cancer: Northern Ireland experience
73. 146 Offering quantitative prognosis to lung cancer patients
74. 26 Audit of gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in patients with EGFR mutation
75. 156 An audit of the quality of curative intent NSCLC radiotherapy
76. 176 Concurrent chemoradiation for lung cancer in routine practice
77. 78 ‘Garbage in, garbage out’ – assessing the quality of new patient histories by thoracic oncologists
78. 163 Efficacy of prophylactic cranial irradiation in small cell lung cancer, subsequent management of brain metastases
79. 141 Improvements in radical radiotherapy outcomes for early NSCLC in Northern Ireland
80. 142 Validation of the MAASTRO clinic cancer prediction tool for overall survival following radical NSCLC radiotherapy
81. A Single Centre Experience of the Introduction of Total Lymphoid Irradiation for Progressive Bronchiolitis Obliterans Syndrome Post Lung Transplantation: Tolerability and Safety
82. Use of speed and extent of PSA response during the first three cycles of docetaxel chemotherapy in metastatic castrate-resistant prostate cancer to predict overall survival.
83. 118 Syndrome of inappropriate antidiuretic hormone (SIADH) in patients with small cell lung cancer & incidence and response to treatment
84. The Impact on PTVs and Normal Lung Dose of Using 18F-FDF PET/CT Simulation on an Already PET/CT Staged Cohort of NSCLC Patients
85. ChemInform Abstract: The Synthesis and Thermal Evaluation of a Novel Cerium Precursor to Grow Thick Ceria Films by Metal-Organic Chemical Vapor Deposition ( MOCVD).
86. Should patients with bone metastases in advanced non-small cell lung cancer be treated any differently than other stage IV patients?
87. Comparison of Northern Ireland Cancer Network to LUCADA headline figures (2006)
88. Target Volume Definition with 18F-FDG PET-CT in the Radiotherapy Treatment Planning Process in Non–small Cell Lung Cancer: Who Should Outline and What?
89. Uptake and delivery of adjuvant chemotherapy in resected non-small cell lung cancer: experience in Northern Ireland Cancer Centre
90. What is the shelf life of PET-CT staging of the mediastinum in non-small cell lung cancer?
91. 18F-FDG PET-CT based target volume definition in non-small cell lung cancer reduces inter-observer variation in already PET-CT staged patients
92. Structural dynamics verification facility study
93. Twisted tail: Spinal epidural lipomatosis responding to chemotherapy in a patient with non-small-cell lung cancer
94. Does PET-CT in the Radiotherapy Treatment Planning Process for Non-small Cell Lung Cancer Alter Treatment Volumes in already PET-CT staged Patients?
95. Induction chemotherapy in non-small cell lung cancer: experience at the Northern Ireland Cancer Centre
96. High dose palliative radiotherapy in NSCLC; 27Gy/6# and 39Gy/13# – is there equivalence?
97. Risk of brain metastases in non-small cell lung cancer patients treated with induction chemotherapy
98. Palliative chemotherapy in non-small cell lung cancer; a year's audit of 101 patients
99. Failure to Achieve PSA Level ≤1 ng/ml Following Neo-adjuvant LHRHa Therapy Predicts for a Lower Rate Biochemical Control and Lower Overall Survival in Localized Prostate Cancer Treated With Radiation Therapy
100. The Role of Radiotherapy in the Treatment of Malignant Pleural Mesothelioma in the Chemotherapy Era
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.